Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Physiomics ( (GB:PYC) ) has issued an update.
Physiomics plc has secured a new contract with GARDP Foundation to provide consultancy support for optimizing the design of an efficacy trial in the Serious Bacterial Infections programme. This contract marks a significant milestone for Physiomics’ Biometrics department, being the third contract since its launch and indicating the department’s potential contribution to the company’s growth. The project aligns with Physiomics’ mission to support clinical development planning and expands its reach into the infectious disease therapeutic area.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, focusing on the development of new therapeutics and personalized medicine solutions. The company combines expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Physiomics has informed the development of over 100 commercial projects and works with clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.
Average Trading Volume: 3,614,153
Technical Sentiment Signal: Sell
Current Market Cap: £955.1K
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.